The latest biotech news - Labiotech.eu

Home News and Trends Page 327

Latest Posts

apogenix glioblastoma cancermark german apg101

News and Trends 17 Feb 2016

Brain Cancer Biomarker is a Magnet for Public Money in Germany

Apogenix (Germany) has been granted €3M for a personalized medicine to treat glioblastoma. It will also use this funding to develop a companion diagnostic test using a specific cancer biomarker, which other German biotechs are also attempting to do… This Heidelberg based-biotech (which we visited on our Labiotech tour of South Germany) is focused on the development of protein Immuno-Oncology therapeutics to treat […]

February 17, 2016 - 3 minutesmins - By Dani Bancroft

abbvie galapagos cystic fibrosis glpg1837

News and Trends 17 Feb 2016

After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

Galapagos (Belgium) is moving forward with their cystic fibrosis drug candidate after promising Phase I results – and still in collaboration with AbbVie (US). Curiouser and curiouser… Galapagos is one of the most hotly-discussed Biotechs in Europe, with around 400 employees and historic IPOs on NASDAQ. It is partnered with several big Pharma, like Gilead, AbbVie, Servier (to develop […]

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

sophia genetics ngs bioinformatics itd

News and Trends 16 Feb 2016

This Swiss Bioinformatics Start-Up is Simplifying NGS and Data Driven Medicine for Hospitals

As one of the most successful medical bioinformatics start-ups in Europe, Sophia Genetics (Switzerland) has now forged a partnership with a US nucleic acid synthesis company to facilitate the transition to Data Driven Medicine. This Swiss start-up led the way in European medical informatics when their software earned accreditation to store patient genomic data – a true […]

February 16, 2016 - 2 minutesmins - By Denise Neves Gameiro

clinical depression glasgow ets6103 e therapeutics

News and Trends 16 Feb 2016

Sorry Scotland, Phase II Trial for Clinical Depression Fails against 55-Year Old Generic

I mean, Clinical depression is a tough indication for Biotech to tackle – particularly when facing off a ’55-year old’ generic (amitriptyline). But e-Therapeutics in Oxford (UK) has more to offer in its pipeline, despite this phase IIb failure in Glasgow. The trial’s aims were to determine whether ETS6103 was an antidepressant capable of treating the patients for […]

February 16, 2016 - 3 minutesmins - By Dani Bancroft

alpaca nejm purpura thrombocytopenia blood titan hercules

News and Trends 16 Feb 2016

World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies

Ablynx, the llama antibody biotech in Belgium, has now proven to be on solid ground regarding their orphan drug for a rare blood disease. Now the New England Journal of Medicine has published their phase II results. Ablynx often makes our biotech headlines, be it with the curious science of their nanobody platform or with their partnerships with […]

February 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

3 biotech unicorns europe

News and Trends 16 Feb 2016

The Only Real European Biotech Unicorns in 2016

Unicorns are private fast-growing companies valued more than a billion euro/dollars. This club is getting bigger and bigger, 146 companies while I’m writing this article (look at the full list on the Wall Street Journal). There is a very reduced number of Biotech unicorns worldwide and even less in Europe. There are actually only 3: […]

February 16, 2016 - 3 minutesmins - By Philip Hemme

ADVERTISEMENT

4d pharma microbiome tucana ucc ibs cork

News and Trends 15 Feb 2016

Europe’s Richest Microbiome Biotech Acquires Irish Start-up To Accelerate!

Have you ever heard of 4D pharma (UK)? Well, it’s become one of the biggest and cash-rich players in the European Microbiome scene. Perhaps the acquisition of this Irish Chronic disease spin-off will bring their name to the spotlight… 4D pharma in Leeds (England) acquired Tucana, a spin-off from the University College Cork (UCC), to complement its therapeutic platform […]

February 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

albert folch lab microfluidics millifluidic seventure

News and Trends 15 Feb 2016

‘Every Droplet Counts’ with €1M Investment into French Microfluidic Start-Up

MilliDrop (France) designs and develops cell culture machines based on millifluidic technology for bacterial research and diagnostics, and has now secured a €1M fund-raising from Seventure. Millidrop will use the fund to start producing trial runs of its first machine, the MilliDrop Analyzer. This machine uses millifluidics technology to culture and analyse micro-organisms. The company is also under the Pierre-Gilles […]

February 15, 2016 - 3 minutesmins - By Dani Bancroft

text mining right direct

News and Trends 15 Feb 2016

Why Text Mining will Revolutionize Big Data in Biotech

Currently, searching information within ‘big data’ is performed via key-words, often resulting in a high number of results that are not always relevant to your initial question. Now, imagine a tool that gives a more precise answer to your question with the same ease of use. That’s the power of text and data mining, and it’s […]

February 15, 2016 - 4 minutesmins - By Jerome Topsent

zimmerman aicuris labiotech s

News and Trends 15 Feb 2016

Celebrating the 10th Birthday of this German Infectious Disease Biotech with the CEO

AiCuris is a Biotech company based on the Bayer Life Sciences park in Wuppertal (Germany). It is working on new anti-infective drugs and is a former spin-off of Germany’s biggest Pharma Company. It’s celebrating its 10th birthday this year, which is good reason to interview the CEO… So AiCuris is working on anti-infective drugs for […]

February 15, 2016 - 4 minutesmins - By Philip Hemme

labiotech week orange

News and Trends 13 Feb 2016

What happened this week? 8 great innovators, PD-L1 combo, Genzyme

Monday: Here are 8 of Forbes’ Under 30 Year Olds Transforming European Biotech Tuesday: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type Wednesday: What’s the situation in France two weeks after the Trial Failure? Thursday: Why is Genzyme still Crazy Successful 5 Years after Sanofi’s Acquisition? Friday: World’s Largest Genome Sequencing Project partners […]

February 13, 2016 - 1 minutemin - By Philip Hemme

genomics england illumina 100 project partner uk

News and Trends 12 Feb 2016

World’s Largest Genome Sequencing Project partners with Global Leader in NGS

Genomics England (UK) today announce a partnership with the Next-Generation Sequencing Giant, Illumina (US), to develop a platform that can be used to improve and automate genome interpretation as part of the 100,000 Genome Project. The tools will operate within the Genomics England secure database to enable researchers and clinicians to access information and reports more readily. […]

February 12, 2016 - 2 minutesmins - By Dani Bancroft

ADVERTISEMENT